Ceruvia Lifesciences

Psychedelic medicine developer

Ceruvia Lifesciences is an active biotechnology company headquartered in Greenwich, Connecticut, developing psychedelic-related medicines for neurological and psychiatric conditions. Its investigational pipeline includes BOL-148, a non-hallucinogenic LSD analog, and synthetic psilocybin candidates. The company announced an $8 million founder-backed investment for an integrated Phase I/II study of BOL-148 in August 2026. Its candidates are investigational and are not available to buy.

Website

ceruvialifesciences.com

Ceruvia Lifesciences catalog

All products · Psychedelic medicine pipeline

Shop the Ceruvia Lifesciences catalog

3 items across 1 shelf

Psychedelic medicine pipeline3 items

• Not reported – Synthetic psilocybinInvestigational
• NYPRG-101 (BOL-148) – Non-hallucinogenic LSD analogInvestigational
• SYNP-101 – Synthetic psilocybinInvestigational